Visomitin

Research use only, not for human use.

Visomitin (SKQ1 bromide, PDTP) is a mitochondria-targeted antioxidant that decreases transmembrane potential and production of reactive oxygen species (ROS).

Visomitin (SKQ1 bromide, PDTP) is a mitochondria-targeted antioxidant that decreases transmembrane potential and production of reactive oxygen species (ROS); prevents neuronal loss and synaptic damage in a rat model of spontaneous Alzheimer’s disease, slows development of age-related ocular pathologies in murine, porcine, bovine, and canine model systems.(In Vitro):Direct treatment of tumor infiltrating leukocytes with Visomitin (SkQ1) does not influence their cytotoxicity against Panc02 cells. While Visomitin does not affect viability of the cell lines, this drug at 500 nM concentration reduces heavily the proliferation of human PDAC cells.(In Vivo):Regarding systemic angiogenic factors, it is observed in serum of Pancreatic ductal adenocarcinoma (PDAC) bearing mice a decrease in KC in the group of continuous treatment with Visomitin (SkQ1). Treatment of the mice with Visomitin increases the level of VEGF molecules. The amount of MIP1a and prolactin is reduced in all Visomitin treatment groups or after the follow-up treatment, respectively. Also, an increase in the IL-6 and IL-13 amount is found in the Visomitin treated groups. TGF-b amount is decreased in the pretreatment setting. On the contrary, all schemes of the Visomitin treatment decrease the NKT cell percentage. The Visomitin treatment has prolonged the median survival of PDAC-bearing mice, but the difference does not reach the level of significance defined.

Direct treatment of tumor infiltrating leukocytes with Visomitin (SkQ1) does not influence their cytotoxicity against Panc02 cells. While Visomitin does not affect viability of the cell lines, this drug at 500 nM concentration reduces heavily the proliferation of human PDAC cells.

Regarding systemic angiogenic factors, it is observed in serum of Pancreatic ductal adenocarcinoma (PDAC) bearing mice a decrease in KC in the group of continuous treatment with Visomitin (SkQ1). Treatment of the mice with Visomitin increases the level of VEGF molecules. The amount of MIP1a and prolactin is reduced in all Visomitin treatment groups or after the follow-up treatment, respectively. Also, an increase in the IL-6 and IL-13 amount is found in the Visomitin treated groups. TGF-b amount is decreased in the pretreatment setting. On the contrary, all schemes of the Visomitin treatment decrease the NKT cell percentage. The Visomitin treatment has prolonged the median survival of PDAC-bearing mice, but the difference does not reach the level of significance defined.

SKQ1 bromide | PDTP

Others

Other Targets

Others

Other Indications

Other Disease

934826-68-3

617.61

C36H42BrO2P

>98% (HPLC)

DMSO: ≥29 mg/mL （ < 1 mg/ml refers to the product slightly soluble or insoluble )

CC1=C(C(=O)C(=CC1=O)CCCCCCCCCC[P+](C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4)C.[Br-]

(10-(4,5-dimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)decyl)triphenylphosphonium bromide

(-20℃)

With Ice Pack

≥ 2 years